MedTrace Logo

A Study of SHR-A1811 in Subjects With Ovarian Cancer

NCT06828354 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-04-20

No results posted yet for this study

Summary

This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.

Conditions

Interventions

DRUG

SHR-A1811

SHR-A1811.

DRUG

Paclitaxel Injection

Paclitaxel Injection.

DRUG

Doxorubicin Hydrochloride Liposome Injection

Doxorubicin Hydrochloride Liposome Injection.

DRUG

Gemcitabine Hydrochloride for Injection

Gemcitabine Hydrochloride for Injection.

DRUG

Topotecan Hydrochloride for Injection

Topotecan Hydrochloride for Injection.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-13
Primary Completion
2027-05-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06828354 on ClinicalTrials.gov